Effect of vitamin D and omega 3 fatty acids co-supplementation on colorectal cancer

Phase 3

Recruiting

• Conditions: Colorectal cancer.; Malignant neoplasm of colon, unspecified

• Registration Number: IRCT20090822002365N22
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients with stage ?? or ??? colorectal cancer and were candidate to receive chemotherapy;
aged 18 years or more;
body mass index range of 18.5-30 kg/m2;
serum 25(OH)D < 30 ng/ml;
not having autoimmune or chronic diseases;
not taking vitamin D and/or omeaga-3 supplements and other vitamin- mineral supplements or parenteral nutrition;
not taking laxative and anti-inflammatory medications;
not allergic to fish and fish products;

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum TNF-a levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany).

Secondary Outcome Measures

Name	Time	Method
Serum levels of Matrix Metalloproteinase-2 (MMP-2). Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum levels of MMP-2 will be assessed by ELISA and Zellbio kit (Zellbio, Germany).;Serum levels of Matrix Metalloproteinase-9 (MMP-9). Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum levels of MMP-9 will be assessed by ELISA and Zellbio kit (Zellbio, Germany).;Serum levels of Alkaline phosphatase (ALP). Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum levels of ALP will be assessed by ELISA and Zellbio kit (Zellbio, Germany).